For more than 20 years, the University of Washington has been home to a database built, maintained and expanded around the goal of helping to prevent health complications from adverse drug reactions, one of the leading causes of injury and death in health care settings.
This year, the UW School of Pharmacy’s Drug Interaction Database, or DIDB — the core research tool in the school’s nonprofit Drug Interaction Solutions organization — is celebrating both a national award for innovation and its independent funding since 2002 through licensing agreements with companies, research institutes and regulatory agencies around the globe.
“The award from the American Society for Clinical Pharmacology & Therapeutics is a great acknowledgement of the impact we’ve had in the drug development space,” said Dr. Isabelle Ragueneau-Majlessi, DIDB co-founder and director of Drug Interaction Solutions. “We built something from scratch at the University of Washington, and now it is internationally recognized as an authoritative research tool, with over 180 organizations from 40 different countries as subscribers.”
